- Trial phase
- Phase 3
- Time to market
- If Phase 3 succeeds, an NDA submission would likely follow in late 2027 or 2028, with potential FDA approval in 2028-2029, assuming standard review timelines.
- Why 6/10
- The next hard, dated catalyst is the Phase 3 pivotal topline readout for osavampator in MDD, expected in H2 2027 (estimated primary completion July 2027 per ClinicalTrials.gov). This is roughly 8-14 months from today, placing it within the ~6-12 month window. Osavampator is a major pipeline value driver, but Neurocrine is a diversified company with the approved blockbuster INGREZZA generating over $1B in quarterly revenue and another Phase 3 program (direclidine in schizophrenia) also reading out in 2027, so the binary risk is contained.
The next major catalyst is the Phase 3 topline readout for osavampator in MDD, expected in the second half of 2027. Positive data would validate a novel AMPA-receptor mechanism in depression and open a large adjunctive-MDD market opportunity. Negative data would remove a key pipeline growth driver but would not threaten Neurocrine's existing INGREZZA franchise. Watch for interim updates or trial-completion announcements from ClinicalTrials.gov (NCT06786624, estimated primary completion July 2027).
Price Chart
Executive Summary
Osavampator (TAK-653 / NBI-1065845) is Neurocrine Biosciences' Phase 3 AMPA receptor positive allosteric modulator for major depressive disorder as an adjunctive therapy. Phase 2 SAVITRI data showed statistically significant MADRS score reductions and good tolerability, leading to a five-study Phase 3 registrational program launched in January 2025. The pivotal readout is expected in the second half of 2027, roughly 8-14 months from now. Osavampator is a meaningful pipeline asset for Neurocrine, but the company is diversified with the already-approved blockbuster INGREZZA (valbenazine) generating over $1B in quarterly revenue, reducing the binary risk.
How It Works
Osavampator is a positive allosteric modulator (PAM) of the AMPA receptor, a protein on brain cells that responds to the neurotransmitter glutamate. Rather than directly activating the receptor, it amplifies the brain's natural glutamate signal by slowing how fast the receptor turns off. This is thought to enhance mood-regulating circuits in the brain. It is taken as a once-daily oral pill.
Trial Status
Neurocrine initiated a five-study Phase 3 registrational program in January 2025 following positive Phase 2 SAVITRI results. The key registrational trial (NCT06786624) is actively recruiting approximately 200 participants with an estimated primary completion date of July 2027. The Phase 2 SAVITRI study met its primary endpoint with a statistically significant 4.3-point placebo-adjusted reduction on the MADRS depression scale at Day 28, deepening to 7.5 points at around two months, with nearly half of patients reaching remission. The drug was well-tolerated with headache as the most common adverse event and no serious adverse events reported.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 topline data readout for osavampator in major depressive disorder, expected in the second half of 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report